Navigation Links
Jefferson receives $11.6M NIH grant to study novel mechanisms of heart failure
Date:5/20/2008

(PHILADELPHIA) Scientists at Jefferson Medical College have received a five-year, $11.6 million grant from the National Heart, Lung and Blood Institute to study molecular mechanisms of cardiac injury that lead to heart failure and potential repair processes that occur in the adult failing heart. This project aims to find data that can be translated into novel therapeutic strategies to improve the failing heart.

This study is unique in that were not only studying factors that contribute to heart failure but we are also looking for cellular and molecular mechanisms that promote repair for the damaged heart, said principal investigator Walter J. Koch, PhD., the W.W Smith Professor of Medicine and director of the Center for Translational Medicine in the Department of Medicine at Jefferson Medical College of Thomas Jefferson University. We will have four core facilities and four different labs working on this grant from a host of different angles. While much of the project will focus on the science of failure and repair, it is also clinically relevant in that we are working with stem cells and pharmaceutical drugs already being given to patients.

An advantage of this type of NIH Program Project Grant is that the four primary projects can be supported by core units. This grant supports four core areas: administrative, surgical, molecular and gene therapy and four main laboratories. In addition to Dr. Kochs leadership in these areas, leaders of these facilities are Andrea Eckhart, Ph.D., Patrick Most, M.D., Erhe Gao, M.D., Ph.D. and Joseph Rabinowitz, Ph.D., all faculty members in the Center for Translational Medicine.

Dr. Kochs group is studying how the enzyme GRK5, which plays a novel role in heart cell signaling and function, is involved in regulating heart cell gene transcription. Gene transcription is part of the two-step process that cells use to read a gene and produce a protein. According to Dr. Koch, abnormal increases in gene transcription are involved in heart failure and heart enlargement.

Another group led by Arthur Feldman, M.D., PhD., the Magee Professor and Chair of Medicine at Jefferson Medical College, will focus on the role of adenosine receptors in the heart. While much is known about their role in protecting the heart when its deprived of oxygen during a heart attack, little is known about what part it plays in healing the heart after injury and in heart failure. Two major adenosine receptor types in the heart appear to have opposite effects. Chronic signaling through one type appears to be detrimental to the heart, resulting in heart failure; whereas signaling through the other receptor appears beneficial. Too much expression of the latter can help repair a heart in failure. Dr. Feldmans research team wants to more closely study the adenosine receptors in the failing heart.

Steven R. Houser, PhD., chair of the Department of Physiology and director of the Cardiovascular Research Center at Temple Universitys School of Medicine, will investigate how the influx of calcium ions can potentially damage the heart or aid in its regeneration, depending on the calcium channels involved. Previous data indicates that an influx of calcium through one type (L) of channel can increase heart damage in the failing heart. But Dr. Houser has found that within the adult heart there are small cells that appear to come from resident cardiac stem cells. These heart cells depend on the (T) type calcium channel and probably aid in normal heart regeneration, though there are too few to repair the heart during a heart attack. Dr. Houser would like to study the calcium signaling characteristics of these heart stem cells to try to understand what mobilizes them, and he is seeking to understand their regenerative potential.

Thomas Force, M.D., the James C. Wilson Professor of Medicine at Jefferson Medical College, has found that a certain type of cancer drug called a tyrosine kinase inhibitor (including the very successful leukemia drug Gleevec), which interferes with a particular enzyme, can cause heart failure. But because the damage appears to be reversible, one theory says that the drugs, instead of damaging the heart cells, may actually hurt heart stem cells and prevent repair. Some early results in the laboratory with stem cell cultured with Gleevec seem to support the theory. Dr. Forces group will continue to test the tyrosine kinase inhibitor drugs to better understand how they affect cardiac stem cells.


'/>"/>

Contact: Rick Cushman
richard.cushman@jefferson.edu
215-955-2240
Thomas Jefferson University
Source:Eurekalert

Related biology news :

1. Jefferson scientists studying the effects of high-dose vitamin C on non-Hodgkin lymphoma patients
2. Jefferson urologists studying regenerated neo-bladder to help spinal cord injury patients
3. BIO-key(R) Receives $335,000 Contract Award From Baltimore Police
4. UCSB receives $3.2 million stem cell grant from state
5. Smithsonian scientist receives 2008 Medal for Excellence in tropical botany
6. Atmel Receives Frost & Sullivans Technology Innovation Award for FingerChip(R) Biometric Sensor
7. McMaster University engineering professor receives Humboldt Research Award
8. BIO-key(R) Receives New Mobile Data Contract Award From Indiana Police Agency
9. UMass Medical School researcher Victor Ambros receives Gairdner Award, Franklin Medal
10. Kansas state flower receives scientific attention
11. BIO-key(R) Receives New Mobile Data Contract Award From Indiana Police Agency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/17/2016)... , March 17, 2016 ABI ... intelligence, forecasts the global biometrics market will reach ... impressive 118% increase from 2015. Consumer electronics, particularly ... embedded fingerprint sensors anticipated to reach two billion ... Dimitrios Pavlakis , Research Analyst at ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... ... May 25, 2016 , ... ... of fracture-specific plating options designed to address fractures of the distal tibia and ... , The Acumed Ankle Plating System 3 is composed of seven plate families ...
(Date:5/25/2016)... Bethesda, Md. (PRWEB) , ... May 25, 2016 ... ... a request for information (RFI) issued by the Office of the National Coordinator ... the patient experience, and determines if clinically relevant data were available when and ...
(Date:5/25/2016)... ... 25, 2016 , ... WEDI, the nation’s leading authority on the use of ... Stellar has been named by the WEDI Board of Directors as WEDI’s president and ... leader with more than 35 years of experience in healthcare, association management and organizational ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... U.S. Food and Drug Administration (FDA) has granted the company’s orphan drug designation ... company’s second orphan drug designation granted by the FDA. , Spinocerebellar ataxia ...
Breaking Biology Technology: